Company / Cash & Equivalents
Apellis Pharmaceuticals, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$466.2M
FY2025
5-year range
$351.2M / $640.2M
FY2021-FY2025
Trend
+13.4%
vs FY2024
Sector context
#46 of 207
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s cash & equivalents of $466M is higher than 78% of companies in the Health Care sector (FY2025). Improved from $351M to $466M over the past 2 years.
Based on SEC 10-K filings.
$466M in FY2025 with a 5-year CAGR of -3.8%. Top quartile in the Health Care sector.
Improved from $351M to $466M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -5.5%
- 5-Year CAGR
- -3.8%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 207This company $466.2M Sector average $669.5M
▼
-30.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -3.8%, indicating a declining trend.
- In FY2025, cash & equivalents increased 13.4% year-over-year.
- Ranks #46 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $466.2M | +13.4% |
| FY2024 | $411.3M | +17.1% |
| FY2023 | $351.2M | -36.4% |
| FY2022 | $551.8M | -13.8% |
| FY2021 | $640.2M | +13.2% |
| FY2020 | $565.8M | +60.7% |
| FY2019 | $352.0M | +99.7% |
| FY2018 | $176.3M | +0.4% |
| FY2017 | $175.6M | +606.4% |
| FY2016 | $24.9M | -30.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026